UBE2O and cancer: In the first study, the UBE2O-α2 axis was postulated as a target for cancer therapies since UBE2O inhibition or Ube2o gene deletion restored α2-subunit levels, or impaired tumor initiation, growth and metastasis, and switched off tumor cell metabolic reprogramming in mice.